Fitness Profiling Links Topoisomerase II Regulation of Centromeric Integrity to Doxorubicin Resistance in Fission Yeast

被引:17
作者
Nguyen, Thi Thuy Trang [1 ,2 ]
Lim, Julia Sze Lynn [1 ,2 ]
Tang, Richard Ming Yi [1 ,2 ]
Zhang, Louxin [4 ,5 ]
Chen, Ee Sin [1 ,2 ,3 ,4 ]
机构
[1] Natl Univ Singapore, Dept Biochem, Singapore 117597, Singapore
[2] NUHS, Singapore, Singapore
[3] Natl Univ Singapore, Synthet Biol Res Consortium, Singapore, Singapore
[4] NUS Grad, Sch Integrat Sci & Engn, Singapore, Singapore
[5] Natl Univ Singapore, Dept Math, Singapore 119076, Singapore
来源
SCIENTIFIC REPORTS | 2015年 / 5卷
关键词
SISTER-CHROMATID SEPARATION; CENP-A; SCHIZOSACCHAROMYCES-POMBE; DNA TOPOISOMERASES; STRUCTURAL BASIS; DISTINCT ROLES; CELL-DEATH; ANTICANCER; GENE; MUTANTS;
D O I
10.1038/srep08400
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Doxorubicin, a chemotherapeutic agent, inhibits the religation step of topoisomerase II (Top2). However, the downstream ramifications of this action are unknown. Here we performed epistasis analyses of top2 with 63 genes representing doxorubicin resistance (DXR) genes in fission yeast and revealed a subset that synergistically collaborate with Top2 to confer DXR. Our findings show that the chromatin-regulating RSC and SAGA complexes act with Top2 in a cluster that is functionally distinct from the Ino80 complex. In various DXR mutants, doxorubicin hypersensitivity was unexpectedly suppressed by a concomitant top2 mutation. Several DXR proteins showed centromeric localization, and their disruption resulted in centromeric defects and chromosome missegregation. An additional top2 mutation could restore centromeric chromatin integrity, suggesting a counterbalance between Top2 and these DXR factors in conferring doxorubicin resistance. Overall, this molecular basis for mitotic catastrophe associated with doxorubicin treatment will help to facilitate drug combinatorial usage in doxorubicin-related chemotherapeutic regimens.
引用
收藏
页数:10
相关论文
共 58 条
[51]   ISOLATION OF TYPE-I AND TYPE-II DNA TOPOISOMERASE MUTANTS FROM FISSION YEAST - SINGLE AND DOUBLE MUTANTS SHOW DIFFERENT PHENOTYPES IN CELL-GROWTH AND CHROMATIN ORGANIZATION [J].
UEMURA, T ;
YANAGIDA, M .
EMBO JOURNAL, 1984, 3 (08) :1737-1744
[52]   Cellular roles of DNA topoisomerases: A molecular perspective [J].
Wang, JC .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (06) :430-440
[54]   On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs [J].
Wu, Chyuan-Chuan ;
Li, Yi-Ching ;
Wang, Ying-Ren ;
Li, Tsai-Kun ;
Chan, Nei-Li .
NUCLEIC ACIDS RESEARCH, 2013, 41 (22) :10630-10640
[55]   Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide [J].
Wu, Chyuan-Chuan ;
Li, Tsai-Kun ;
Farh, Lynn ;
Lin, Li-Ying ;
Lin, Te-Sheng ;
Yu, Yu-Jen ;
Yen, Tien-Jui ;
Chiang, Chia-Wang ;
Chan, Nei-Li .
SCIENCE, 2011, 333 (6041) :459-462
[56]   The roles of fission yeast Ase1 in mitotic cell division, meiotic nuclear oscillation, and cytokinesis checkpoint signaling [J].
Yamashita, A ;
Sato, M ;
Fujita, A ;
Yamamoto, M ;
Toda, T .
MOLECULAR BIOLOGY OF THE CELL, 2005, 16 (03) :1378-1395
[57]   Doxorubicin Enhances Nucleosome Turnover around Promoters [J].
Yang, Fan ;
Kemp, Christopher J. ;
Henikoff, Steven .
CURRENT BIOLOGY, 2013, 23 (09) :782-787
[58]   An ancestral haplotype defines susceptibility to doxorubicin nephropathy in the laboratory mouse [J].
Zheng, Zongyu ;
Pavlidis, Paul ;
Chua, Streamson ;
D'Agati, Vivette D. ;
Gharavi, Ali G. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (07) :1796-1800